Skip to main content
Premium Trial:

Request an Annual Quote

AlgoNomics Gives Genmab Access to Bioinformatics Platform in Agreement

This article corrects the fact that AlgoNomics' platform -- not Genmab's platform, as originally reported -- is intended for T-cell epitope identification.

NEW YORK, May 12 (GenomeWeb News) - AlgoNomics  has granted Genmab access to its Epibase structural bioinformatics platform for three years, the companies said today.

 

The AlgoNomics platform is intended for T-cell epitope identification. Epibase can be used "to validate the intrinsically low immunogenicity of our fully human therapeutic antibody leads that are currently in clinical and pre-clinical phases," said Jan van de Winkel, Genmab CSO, in a statement.

 

Financial details of the agreement were not disclosed.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.